5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Indian Journal of Cancer

• Publication date

  2005-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/0019-509X.16697PMID 16141507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The treatment of advanced gastric cancer: new findings on the activity of the taxanes.

  2004cited by this paper
• Palliative chemotherapy for advanced gastric cancer.

  2004cited by this paper
• Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

  2004cited by this paper
• Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.

  2004cited by this paper
• Docetaxel-based chemotherapy in the treatment of gastric cancer.

  2003cited by this paper
• Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.

  2003cited by this paper
• Randomized phase II study of weekly 24 h infusion of high dose 5-FU ± folinic acid (HD-FU±FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953

  2001cited by this paper
• Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma

  2001cited by this paper
• Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.

  2001cited by this paper
• Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.

  2000cited by this paper
• Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

  1997cited by this paper
• Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

  1997cited by this paper
• Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

  1997cited by this paper
• Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

  1995cited by this paper
• A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

  1994cited by this paper
• Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.

  1994cited by this paper
• Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

  1993cited by this paper
• Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons.

  1992cited by this paper
• Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

  1991cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• CHEMOTHERAPY OF GASTRIC CANCER.

  1964cited by this paper

• Silencing of Long Noncoding RNA LINC00324 Interacts with MicroRNA-3200-5p to Attenuate the Tumorigenesis of Gastric Cancer via Regulating BCAT1

  2020cites this paper
• Protective Effect of Hesperidin on Humoral and Cell-mediated Immunity in Rat Model

  2020cites this paper
• Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study

  2019cites this paper
• Haematological effects of leaf extract of Moringa oleifera Lam in normal and myelo-suppressed wistar rats

  2018cites this paper
• Down-regulation of the let-7i facilitates gastric cancer invasion and metastasis by targeting COL1A1

  2018cites this paper
• Effect and mechanism of recombinant human granulocyte colony-stimulating factor on diarrhea caused by leukopenia in New Zealand rabbits

  2018cites this paper
• Distribution of gastric carcinoma in an area with a high prevalence of Helicobacter pylori.

  2017influential citation
• Evaluation of the Use of Granulocyte Colony-Stimulating Factors (G-CSFs) for Neutropenia Primary Prophylaxis in Solid Tumors at a Tertiary Care Hospital, Retrospective Study

  2017cites this paper
• Treatment effect of low intensity pulsed ultrasound on leukopenia induced by cyclophosphamide in rabbits.

  2017cites this paper
• Myelo-protective and haematopoietic effects of seed extract fractions of Phoenix dactylifera in Wistar rats

  2016cites this paper
• Burden of gastrointestinal cancer in Asia; an overview

  2015cites this paper
• Myeloprotective activity of crude methanolic leaf extract of Cassia occidentalis in cyclophosphamide-induced bone marrow suppression in Wistar rats

  2015cites this paper
• ECF with Infusional Fluorouracil for 5 Days in Locally Advanced and Metastatic Gastric Cancer, Is It Better than the Standard?

  2013cites this paper
• Trend analysis of gastric cancer and colorectal cancer mortality in Iran, 1995-2003

  2011cites this paper
• Myelo-protective activity of aqueous and methanolic leaf extracts of vitex doniana in cyclophosphamide-induced myelo-suppression in wistar rats

  2011cites this paper
• Bayesian analysis of gastric cancer mortality in Iranian population

  2009cites this paper
• Prognostic factors in gastric cancer using log-normal censored regression model.

  2009cites this paper
• Myeloprotective effects of rosiglitazone, an insulin sensitizer, on 5-fluorouracil-induced toxicity

  2007cites this paper